Zhang Caihui, Gao Sihao, Sun Zhixing, Wang Tao, Song Hongmei
Department of Pediatrics, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Department of Dermatology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Orphanet J Rare Dis. 2025 Jun 23;20(1):318. doi: 10.1186/s13023-025-03748-7.
Stiff skin syndrome (SSS) is a rare, non-inflammatory skin disease with a pronounced restriction in joint mobility. In this study, we aim to report Chinese pediatric patients with SSS in our center and summarize the clinical features of the disease through literature review.
A retrospective study was conducted on 16 pediatric patients diagnosed with SSS at Peking Union Medical College Hospital between January 2014 and January 2024, based on clinical manifestations, laboratory tests, and skin biopsy findings. Among these cases, two were classified as widespread SSS, and 14 as segmental SSS. Additionally, a review of relevant literature published between January 2000 and January 2024 involving 138 cases of pediatric SSS was also conducted. The clinical characteristics, treatment, and prognosis of these 154 patients were summarized. The age of onset in patients was 2.0(0.5, 4.8) years, with an average age at diagnosis being 9.0(5.0, 13.0) years. Thigh skin sclerosis (81, 52.6%) was the most common manifestation observed in these patients. Joint restriction was present in 55(35.7%) patients. Patients with joint contractures had longer diagnostic delays compared with those without joint contractures. Patients were primarily treated with physical therapy, while some patients received medications such as mycophenolate mofetil (MMF), losartan, and secukinumab. However, the prognosis varied.
The diagnosis of SSS should involve a thorough investigation of family history, detailed physical examination, comprehensive pathological assessment, genetic testing when applicable, and careful exclusion of other scleroderma-like diseases. Currently, there is limited evidence supporting the use of systemic treatment options targeting the transforming growth factor-β or interleukin-17 pathways (such as MMF, losartan, and secukinumab) to slow disease progression. However, these treatments are not capable of reversing established skin lesions, and further investigations are imperative to assess their therapeutic efficacy in SSS.
僵皮综合征(SSS)是一种罕见的非炎症性皮肤病,关节活动度明显受限。在本研究中,我们旨在报告我院收治的中国儿童SSS患者,并通过文献复习总结该病的临床特征。
对2014年1月至2024年1月在北京协和医院确诊为SSS的16例儿科患者进行了回顾性研究,依据临床表现、实验室检查及皮肤活检结果。其中,2例为泛发性SSS,14例为局限性SSS。此外,还对2000年1月至2024年1月发表的涉及138例儿童SSS的相关文献进行了复习。总结了这154例患者的临床特征、治疗及预后情况。患者发病年龄为2.0(0.5,4.8)岁,确诊时平均年龄为9.0(5.0,13.0)岁。大腿皮肤硬化(81例,52.6%)是这些患者中最常见的表现。55例(35.7%)患者存在关节活动受限。有关节挛缩的患者与无关节挛缩的患者相比,诊断延迟时间更长。患者主要接受物理治疗,部分患者使用了霉酚酸酯(MMF)、氯沙坦和司库奇尤单抗等药物。然而,预后各不相同。
SSS的诊断应全面调查家族史、详细体格检查、综合病理评估,必要时进行基因检测,并仔细排除其他硬皮病样疾病。目前,支持使用针对转化生长因子-β或白细胞介素-17通路的全身治疗方案(如MMF、氯沙坦和司库奇尤单抗)来延缓疾病进展的证据有限。然而,这些治疗无法逆转已形成的皮肤病变,必须进一步研究以评估其在SSS中的治疗效果。